Home/Pipeline/SP-104

SP-104

Fibromyalgia

Preclinical/Phase 1In development

Key Facts

Indication

Fibromyalgia

Phase

Preclinical/Phase 1

Status

In development

Company

SCILEX

About SCILEX

Scilex Holding Company (Nasdaq: SCLX) is a revenue-generating biopharmaceutical company dedicated to becoming a global leader in non-opioid pain management. Its strategy combines the commercialization of acquired, approved products like ZTlido®, Elyxyb®, and Gloperba® with the development of a proprietary pipeline, including the late-stage injectable candidate SEMDEXA™ for sciatica. Founded in 2013 and headquartered in Palo Alto, California, Scilex is positioned at the critical intersection of drug delivery innovation and the urgent societal need to address the opioid crisis.

View full company profile

Therapeutic Areas

Pain Management Neurology

Other Fibromyalgia Drugs

Drug	Company	Phase	Status
Sequential Dialysis Technique	Halberd	Discovery	Conceptual
Stanza	Swing Therapeutics	Approved	Active
Fibromyalgia Studies	Pacific Clinical Research Medical Group	Phase 2/3	Active
Fibromyalgia Biomarkers	Paradise Genomics	Discovery	Active
AXS-14	Axsome Therapeutics	Phase 3	Active
SP-104 (low-dose naltrexone DR capsules)	Scilex Holding	Preclinical	Development